Treatment costs of three nail lacquers used in onychomycosis

Journal of Dermatological Treatment

Volumn 16, Issue 5-6, 2005, Pages 299-307

  Marty, Jean Paul L ^a   Lambert, Julien ^b   Jäckel, Andreas ^c   Adjadj, Lucie ^d  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Galderma Laboratorium GmbH   (Germany)

^d Galderma R and D   (France)

Author keywords

Amorolfine; Ciclopirox; Cost analysis; Onychomycosis; Tioconazole; Transungual drug delivery system

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROX; CICLOPIROXOLAMINE; TIOCONAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FRANCE; GERMANY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; ONYCHOMYCOSIS; PRIORITY JOURNAL;

ADULT; ANTIFUNGAL AGENTS; DRUG COSTS; EUROPE; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IMIDAZOLES; MALE; MORPHOLINES; ONYCHOMYCOSIS; PYRIDONES;

EID: 31644449202     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500375965     Document Type: Article

References (24)

1. Ravnborg L, Baastrup N, Svejgaard E. Onychomycosis in HIV-infected patients. Acta Derm Venereol. 1998;78:151-2.
2. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc. 2000;90:495-501.
3. Pittrof F, Gerhards J, Erni W, Klecak G. Loceryl nail lacquer - realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol. 1992;17(Suppl 1):26-8.
4. Baran R. Ciclopirox nail lacquer: the first prescription topical therapy for onychomycosis - Introduction. J Am Acad Dermatol. 2000;43(4 Pt 2):S55-S56.
5. Marry J-PL. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol. 1995;4(Suppl 1):S17-S21.
6. Marty J-P, Baran R. Transungual drug delivery systems: what's new and relevant. In: Baran R, Maibach HI, eds. Textbook of cosmetic dermatology, 2nd edn. London: Martin Dunitz, 1998:95-7.
7. Tulli A, Ruffilli MP, De Simone C. The treatment of onychomycosis with a new form of tioconazole. Chemioterapia. 1988;7:160-3.
8. Roberts DT, Hay RJ, Doherty VR, Richardson MD, Clayton YM. Topical treatment of onychomycosis using bifonazole 1% urea/40% paste. Ann N Y Acad Sci. 1988;544:586-7.
9. Hay RJ, Roberts DT, Doherty VR, Richardson MD, Midgley G. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol. 1988;13:164-7.
10. Lecha M, Alsina M, Torres-Rodriguez JM, de Erenchun FR, Mirada A, Rossi AB. An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res. 2002;63:366-79.
11. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol. 2001;145(Suppl 60):15-19.
12. Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol. 2000;43(4 Suppl):S81-S95.
13. Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol. 1992;17(Suppl 1):44-9.
14. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol. 1992;17(Suppl 1):41-3.
15. Vidal. OVP-Editions du vidal, 2001.
16. MIMS. London: Haymarket Medical Publications, July 2003.
17. Rote List . Guide to drugs marketed in Germany (including EU-approved drugs & particular devices). Editio Cantor Verlag, 2003.
18. Pianetasalute, 2003.
19. Hay RJ, Mackie RM, Clayton YM. Tioconazole nail solution - an open study of its efficacy in onychomycosis. Clin Exp Dermatol. 1985;10:111-15.
20. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol. 1992;126(Suppl 39):23-7.
21. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol. 1999;141(Suppl 56):1-4.
22. IMS; data 2003.
23. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2 Pt 1):244-8.
24. Sais G, Jucgla A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol. 1995;132:758-61.